Kornimate/medical-research-clean huggingface dataset:
body composition and white adipose tissue inflammation

Conditions: Breast Cancer; Prostate Cancer; Body Composition; White Adipose Tissue Inflammation

Summary: the investigators want to find a better way to predict the risk of having fatty tissue inflammation by using a different approach to finding out body fat composition. in this study, the investigators want to estimate the body fat composition using a dexa scan. dexa stands for dual energy x-ray absorptiometry. it is the standard and established test to determine bone mineral density (how strong the bones are) to diagnose osteoporosis. this test can also be used to determine the body composition including percent body fat and lean mass. the investigators will compare the participants dexa scan results for body fat composition to the inflammation found in the breast tissue from the mastectomy to see if there is a relationship. if successful, this may help us predict which patients may be at risk for breast cancer in the future. in addition, the investigators will compare the participants dexa scan results for body fat composition and inflammation found in the fat tissue from the mastectomy or prostatectomy to the level of exercise activity as measured by a short questionnaire to see if there is a relationship. the investigators will also measure the participants waist to hip ratio. finally, at the time the participant has blood drawn for their standard presurgical testing, the investigators will also test the blood for prediabetes using a blood test called hemoglocin a1c. the investigators will also measure for the participants waist to hip ratio, and a hgb a1c blood drawn will be take at the time of presurgical testing. if not feasible, hgb a1c can be drawn at a separate visit prior to the dexa scan. if successful, this may help us predict which patients may be at risk for breast cancer in the future.


Eligibility criteria:
inclusion criteria: * age ≥ 18 * female * all bmis * patients undergoing mastectomy at mskcc (i.e. nipple-sparing mastectomy, skin-sparing mastectomy, simple mastectomy, modified radical mastectomy, radical mastectomy); mastectomy may be either prophylactic or therapeutic. or * patients undergoing hysterectomy at mskcc * history of prior breast surgeries/procedures is acceptable exclusion criteria: * pregnancy (confirmed or suspected); * inability to lay supine on equipment table and maintain the position for the necessary time; * weight superior to the maximum allowed by the dexa machine (over 350 lbs or 158 kg); * greater than 10% baseline weight loss in the past year; * planned surgical procedure is not a mastectomy (i.e. breast conservation surgery or other non-mastectomy procedure; such as lumpectomy) or hysterectomy * metastatic cancer * history of wasting syndromes or cachexia * use of daily nsaids, aspirin, or steroids (other than inhaled or topical) within 30 days of surgery * use of neoadjuvant systemic or radiation therapy.

Keywords: dexa scan 15-235
study of subluxation lens biometrics and postoperative intraocular lens stability

Conditions: Subluxation of Lens

Summary: to compare the accuracy of four lens diameter measurement methods and to study the influencing factors of intraocular lens deviation after operation


Eligibility criteria:
inclusion criteria: (1) subluxation of the lens is less than 180 degrees; (2) part of the edge of the lens can be seen in the pupil area after the pupil is dilated exclusion criteria: (1) total dislocation of the lens to the vitreous cavity (2) patients with small eyeballs and small eyelid fissures (3) patients younger than 18 years old (4) congenital cataracts in both eyes (5) corneal dystrophy or endothelial cell insufficiency (6) chronic uvea inflammation (7) progressive fundus disease (8) fragile capsular bag (9) retinitis pigmentosa or pseudocapsular exfoliation syndrome
study the safety and effectiveness of mk7009 in hepatitis c infected patients (mk-7009-004)(completed)

Conditions: Hepatitis C

Summary: the purpose of this study is to investigate the effectiveness, safety, and tolerability of mk7009 in patients infected with hepatitis c


Eligibility criteria:
inclusion criteria: * subject is a man or a woman aged 18 to 55 years of age. * subject has chronic hepatitis c * subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period exclusion criteria: * patient has evidence of advanced liver disease. * patient has human immunodeficiency virus (hiv) * patient has hepatitis b
a study to test whether study drug bay1128688 brings pain relief to women with endometriosis and if so to get a first idea which dose(s) work best

Conditions: Endometriosis

Summary: purpose of the study is to test whether study drug bay1128688 brings relief for pain to women with endometriosis and if so to get a first impression which dose(s) work best.


Eligibility criteria:
inclusion criteria: * women of at least 18 years of age at the time of signing of informed consent * women with endometriosis confirmed by at least one of the two criteria: * surgery within the last 10 years * imaging within the last 12 months * moderate to severe pelvic pain which will be assessed over a period of 28 days * willingness to use only ibuprofen as rescue pain medication for endometriosis-associated pelvic pain * willingness to use non-hormonal barrier method for contraception (here spermicide-coated condoms) from screening visit until the end of the study (unless adequate contraception is achieved by vasectomy of the partner or use of copper intrauterine device \[iud\] or commitment to abstinence) and refrain from using hormonal contraception exclusion criteria: * pregnancy or lactation (more than three months since delivery, abortion, or lactation before start of treatment) and no wish for pregnancy during the study * altered bilirubin metabolism and liver function at visit 1 * requirement to use pain medications for reasons other than endometriosis * contraindications to using ibuprofen * signs of hyperandrogenism * absence of menstrual cycles and/or abnormal vaginal/genital bleeding * history of hysterectomy, tubal-ligation or bilateral ovariectomy * uncontrolled thyroid disorder
effectiveness and safety of finerenone in chinese ckd patients without diabetes mellitus

Conditions: Chronic Kidney Diseases

Summary: background： this study aimed to evaluate the effectiveness and safety of finerenone in patients with chronic kidney disease (ckd) without diabetes mellitus(dm), however, evidence based on both clinical trails and real-world data are limited. methods: patients with ckd without dm were enrolled in this study from december 2022 to december 2024. in conjunction with the established treatment regimen for chronic kidney disease (ckd), study participants were additionally administered finerenone. to evaluate the therapeutic impact and safety profile of the intervention, three primary biomarkers were monitored: 24-hour urinary protein (utp), estimated glomerular filtration rate (egfr), and serum potassium (sk+). these parameters were closely measured on a monthly basis, starting from the point of enrollment and continuing for a duration of twelve months or possibly longer.

chronic kidney disease (ckd) is a significant global health issue that leads to end-stage renal disease (esrd) and is associated with rising healthcare costs and high mortality rates. its prevalence is increasing due to aging populations and the growing rates of diabetes and hypertension. ckd causes severe complications and significantly impairs patients' quality of life. there are notable disparities in ckd incidence and treatment among different socioeconomic groups, and many healthcare systems struggle with the challenges of managing and funding the disease. in terms of treatment, there is a particular bottleneck in addressing ckd among non-diabetic patients. currently, the focus for non-diabetic ckd patients is on controlling blood pressure and proteinuria. however, new treatments such as finerenone show promise in reducing ckd progression and cardiovascular risks in diabetic patients. ongoing research aims to explore the effectiveness of these treatments in non-diabetic ckd patients as well. it is important to note that further studies are required to confirm the safety and efficacy of finerenone in these specific populations.

Eligibility criteria:
inclusion criteria: * ckd without diabetes exclusion criteria: * ckd with diabetes

Keywords: chronic kidney disease finerenone
senescence and the early ageing phenotype after chemotherapy for testicular cancer: the sea-cat study

Conditions: Testicular Cancer

Summary: cisplatin-combination chemotherapy causes inevitably dna damage by platinum-dna adduct formation of both tumor cells but also healthy cells. it therefore stands to reason that testicular cancer treatment causes an increased burden of senescent cells, which causes upregulation of the sasp resulting in a pro-inflammatory phenotype. the investigators hypothesize that this may be an important mechanism behind development of late effects and an early ageing phenotype after treatment for testicular cancer.


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria: * diagnosed with metastatic testicular cancer in 1999-2012 (stage ii or higher) * received first-line cisplatin-based chemotherapy * was younger than 50 years of age at start of chemotherapy in order to be eligible to participate in the longitudinal part of this study, a subject must meet all of the following criteria: chemotherapy-group: * diagnosis of metastatic testicular cancer (stage ii or higher) * is about to start with first-line cisplatin-based chemotherapy * younger than 50 years of age at diagnosis of metastatic testicular cancer stage i control-group: * diagnosis of testicular cancer stage i disease * younger than 50 years of age at diagnosis of testicular cancer exclusion criteria: a potential subject who meets any of the following criteria will be excluded from participation in this study: - not able to provide informed consent (in example in case of mental or psychiatric disability)
a retrospective comparison of the efficacy and safety of celsior® in pediatric cardiac surgery for transposition of the great vessels

Conditions: Transposition of Great Vessels

Summary: celsior® is an organ preservation solution used for the harvesting and the preservation of solid organs. its use as a crystalloid cardioplegia solution has been established recently. its main advantage is the long duration of myocardial protection. compared to the other cardioplegia solutions, it allows a reduced amount of solution administered during the surgery and fewer interruptions during the intervention for the administration of supplemental doses of cardioplegia for long and complex operations. the objective of this register is to compare the safety and the efficacy of celsior® to the old cardioplegia solution saint-thomas used as cardioplegia solution in surgery of the transposition of great vessels, the arterial switch operation.


Eligibility criteria:
inclusion criteria: * patient of neonatal age at the time of the intervention * patients with a transposition of the great vessels with intact septum and with the arterial switch operation performed as a corrective procedure * celsior® used as cardioplegia solution between 2012 and 2019 * saint-thomas used as cardioplegia solution (control group) between 2005 and 2011 exclusion criteria: * major cardiovascular malformations needing correction during the surgery for the transposition of great vessels including : interventricular communication, coarctation of the aorta, interruption of the aortic arch * significant anomalies of coronary arteries origin or paths including : intramural course, single coronary ostium * opposition to participate in this retrospective research
cardiac (cmri) assessment of acromegaly

Conditions: Acromegaly

Summary: in this study, the investigators will evaluate the cardiac structure and function, focusing on the myocardial water content and interstitial fibrosis, in patients with active acromegaly in comparison with 1) healthy volunteers, 2) the same acromegalic patients that have received efficient therapy. the investigators hypothesize that the myocardial water content in acromegaly is increased as these patients present with sodium and water retention and that this myocardial water infiltration will improve with efficient treatment of the disease. they will thus assess using cmri, this parameter by measuring the myocardial transverse relaxation time (t2), reflecting water content in the myocardium.

patients with acromegaly have left ventricular (lv) hypertrophy and dysfunction on echocardiography, but only very few studies have been performed using cardiac magnetic resonance imaging (cmri), currently the reference modality is assessment in cardiac geometry function. in addition, no data are available on right ventricular (rv) and atrial structure and function. the pathophysiology of the cardiac involvement in acromegaly may be related to increase myocardiac water content and/or interstitial myocardiac fibrosis. the main objective of sthe study is to compare the myocardial water content in patients with acromegaly and in healthy volunteers. secondary objectives of the study are to evaluate : 1. interstitial fibrosis and the structure and the function of lv and rv in acromegalic patients in comparison with healthy volunteers; 2. the reversibility of the cardiac involvement (water content, fibrosis, lv and rv structure and function) after efficient treatment of acromegaly; 3. the elasticity of aorta in acromegalic patients in comparison with healthy volunteers and with the post-treatment state. twenty acromegalic patients will be included in order to dispose of 15 patients that will completed the study and the same number of age- and bmi-adjusted healthy volunteers will be included.

Eligibility criteria:
inclusion criteria: * active acromegaly as defined by the usual diagnostic criteria (de novo patients or patients uncontrolled by previous treatments). * healthy volunteers matched for age, sex and bmi with the patients of the group 1 exclusion criteria: * history of coronary heart disease (acute or chronic myocardial ischemia) * acute or chronic renal failure (creatinin clearance 30 ml/min/l,73m2) * contraindication of mri * hypersensitivity to gadolinium * pregnancy

Keywords: acromegaly, water retention myocardial fibrosis left ventricular hypertrophy left ventricular dysfunction
evaluating results of neusidl corneal inserter in descemet's stripping automated endothelial keratoplasty (dsaek)

Conditions: Fuchs' Corneal Endothelial Dystrophy

Summary: this project compares the neusidl corneal injector (nci) device developed by fischer surgical, inc. for the delivery of tissue into the eye in dsaek surgery to the current standard forceps insertion dsaek technique. the goal of this study is to examine the damage to the corneal endothelium resulting from the use of the nci device in comparison to the use of our standard surgical dsaek technique over time.


Eligibility criteria:
inclusion criteria: * age 21 and over * a diagnosis of fuchs' corneal endothelial dystrophy exclusion criteria: * under age 21 * diagnosis of advanced glaucomatous disease * diagnosis of significant retinal disease * diagnosis of any other corneal dystrophy * previous corneal transplant surgery * previous glaucoma surgery * previous retinal surgery * previous refractive surgery
assessment of patients quality of life treated with three arthrum h 2% joint injections

Conditions: Knee Osteoarthritis

Summary: the reduction of functional limits and disablilities induced by knee osteoarthritis as well as improvement of patients quality of life is a public health need registered amongst the priorities established by the french law of august 9th 2004 relative to public health policy. however, the response to this need is not limited to treatment with health products. this clinical trial in real life on arthrum h 2% device aims to analyse patients quality of life treated by intraarticular injections, eventually for several years, by difference of usual clinical trials. this open, prospective, multicentric study aims to analyse, in patient care, the impact of three intraarticular injections of arthrum h 2% on quality of life over a period of 6 months (d180) in the symptomatic treatment of knee osteoarthritis.

parameters used to determine treatment outcomes include: "short-form 12 health survey" (sf-12), pain score of the western ontario mcmaster universities osteoarthritis index (womac a)

Eligibility criteria:
inclusion criteria: * men or women aged over 40; * suffering from symptomatic knee osteoarthritis radiologically confirmed less than 12 months ago and stage i, ii or iii according to kellgren (knee in extension) and with minimal pain on walking (womac a1) of two points on the likert scale * patient able to understand the trial procedure and give his/her consent to take part, in writing; * patient geographically stable during the trial; * patient affiliated to the french social security regime or benefiting from such a french regime. exclusion criteria: * inflammatory arthritis; * progressive infectious condition of the knee being studied; * previous treatment with viscosupplementation for at least one year; * injection of corticoids into the knee studied for less than two months; * known hypersensivity to hyaluronic acid or substances with similar activity; * pregnant or breast-feeding women; * patient under guardianship or tutorship or under juridicial protection; * patient currently taking part in another clinical research study.

Keywords: hyaluronic acid knee osteoarthritis quality of life
the effects of observer presence and type on patients' perception of exercise after bone tumor resection-a qualitative study

Conditions: Bone Cancer; Tumor

Summary: the primary aim of the study is to investigate the effects of supervised exercise, telerehabilitation and home-based exercise on patient perception in patients who have undergone bone tumor resection. the secondary aim of the study is to identify the barriers to starting exercise in these patients.

an exploratory-descriptive qualitative study will be conducted. there will be three groups in the study with each of them will consist of ten participants. within the scope of the study, each group will perform a similar exercise program, 2 sessions a week, for 6 weeks, in one of the 3 groups below; group 1: exercising under the supervision of a face-to-face physiotherapist, group 2: exercise under the observation of the physiotherapist via video-conference (telerehabilitation), group 3: exercising in the absence of the observer (home based exercise program). the exercises to be applied to the groups will include breathing exercises, passive range of motion exercises within the pain limit for the joints associated with the surgery area, and strengthening exercises for the non-surgical areas. semi-structured focus group interviews will be held with the participants twice, before and after the 6-week exercise program. in the semi-structured focus group interviews, the same questions will be asked to all participants and the verbal answers to these questions will be recorded with voice recorders. compared to taking notes by hand; it will be preferable to record the conversation with a voice recorder because it has advantages such as recording all the interviews and allowing the interviewer to focus on the interview. in the pre-exercise interview, questions will be asked to determine the patient's views about exercises and the barriers to starting the exercise. in the interview held at the end of the exercise program, questions will be asked to learn the views/perceptions of the patients about the results of the exercise program. thematic analysis method will be used in the evaluation of the data.

Eligibility criteria:
inclusion criteria: * individuals aged between 18 and 65, * individuals without communication problems, * individuals who have been diagnosed with a bone tumor for the first time and who have undergone resection surgery exclusion criteria: * uncontrollable arrhythmia and/or hypertension * presence of advanced sensory deficit * visual and hearing problems * not having sufficient communication skills (mini mental test score below 24 points) * patients undergoing head and neck bone resection

Keywords: bone cancer exercise telerehabilitation
investigation on the efficacy of wo 2085 moisturising cream for breast cancer patients suffering from vulvovaginal dryness

Conditions: Vulvovaginal Atrophy

Summary: the aim of the study is to gain further experience with regard to the performance of the medical device wo2085 moisturising cream for breast cancer patients undergoing chemotherapy or treatment with anti-oestrogens / aromatase inhibitors

the goal of this application study was to answer the question as to whether the application of wo2085 moisturising cream for breast cancer patients undergoing chemotherapy or treatment with anti-oestrogens / aromatase inhibitors can result in an improvement in the subjective symptoms and objective diagnoses of vulvovaginal dryness while also ensuring good tolerability.

Eligibility criteria:
inclusion criteria: * women with breast cancer undergoing chemotherapy or therapy with aromatase inhibitors or anti-oestrogens (either at present or up to 3 months after ending treatment) and with symptoms of vulvovaginal dryness since the start of tumour treatment * written declaration of consent for the voluntary participation in the study is present exclusion criteria: * women who suffered symptoms of vulvovaginal dryness prior to the start of tumour treatment * patients undergoing radiation therapy * patients with other tumours * a current vaginal infection * medical conditions related to the vulva or vagina * current additional therapy of vulvovaginal dryness or vulvovaginal atrophy * women who are not able to participate properly in this study * current alcohol and/or drug abuse * pregnant or lactating women

Keywords: vulvovaginal dryness
rct of nipgt for aneuploidy and morphology compared with morphology alone in ivf

Conditions: Preimplantation Diagnosis

Summary: this study is to compare the efficacy in embryo selection based on morphology alone compared to morphology and non-invasive preimplantation genetic testing for aneuploidy (nipgt-a) in infertile women undergoing in vitro fertilization (ivf). we supposed the embryo selection based on morphology and nipgt-a results in a higher live birth rate and a lower miscarriage rate in ivf as compared with that based on morphology alone. therefore we would like to conduct a double-blind randomized controlled trial. infertile women undergoing ivf will be enrolled. the spent culture medium (scm) of each blastocyst will be frozen individually. they will be randomized into two groups: (1) the intervention group based on morphology and nipgt-a and (2) the control group based on morphology alone. in the control group, blastocysts with the best quality morphology will be replaced first. in the intervention group, blastocysts with the best morphology and euploid result of scm will be replaced first.the primary outcome is a live birth per the first embryo transfer. we would like to compare live birth rates and miscarriage rates between the two groups.


Eligibility criteria:
inclusion criteria: * women aged less than 43 years at the time of ovarian stimulation * at least two blastocysts suitable for freezing on day 5 or 6 after oocyte retrieval exclusion criteria: * less than two blastocysts suitable for freezing on day 5 or 6 after oocyte retrieval; * women undergoing pgt for monogenic diseases or structural rearrangement of chromosomes; * use of donor oocytes; * hydrosalpinx shown on pelvic scanning and not surgically treated